SG10201500208SA - Npp1 fusion proteins - Google Patents

Npp1 fusion proteins

Info

Publication number
SG10201500208SA
SG10201500208SA SG10201500208SA SG10201500208SA SG10201500208SA SG 10201500208S A SG10201500208S A SG 10201500208SA SG 10201500208S A SG10201500208S A SG 10201500208SA SG 10201500208S A SG10201500208S A SG 10201500208SA SG 10201500208S A SG10201500208S A SG 10201500208SA
Authority
SG
Singapore
Prior art keywords
fusion proteins
npp1 fusion
npp1
proteins
fusion
Prior art date
Application number
SG10201500208SA
Other languages
English (en)
Inventor
Anthony Quinn
Alex J Harvey
Zhinan Xia
Original Assignee
Synageva Biopharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synageva Biopharma Corp filed Critical Synageva Biopharma Corp
Publication of SG10201500208SA publication Critical patent/SG10201500208SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/04—Phosphoric diester hydrolases (3.1.4)
    • C12Y301/04001—Phosphodiesterase I (3.1.4.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/007—Vectors comprising a special translation-regulating system cell or tissue specific
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
SG10201500208SA 2010-03-12 2011-09-15 Npp1 fusion proteins SG10201500208SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34006610P 2010-03-12 2010-03-12
PCT/US2011/028233 WO2011113027A2 (fr) 2010-03-12 2011-03-11 Protéines de fusion npp1

Publications (1)

Publication Number Publication Date
SG10201500208SA true SG10201500208SA (en) 2015-03-30

Family

ID=44564171

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201500208SA SG10201500208SA (en) 2010-03-12 2011-09-15 Npp1 fusion proteins
SG10202100341XA SG10202100341XA (en) 2010-03-12 2011-09-15 Npp1 fusion proteins

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10202100341XA SG10202100341XA (en) 2010-03-12 2011-09-15 Npp1 fusion proteins

Country Status (10)

Country Link
US (7) US8846603B2 (fr)
EP (1) EP2545080B1 (fr)
JP (3) JP5735665B2 (fr)
BR (1) BR112013023010B1 (fr)
CL (1) CL2013002607A1 (fr)
ES (2) ES2628841T3 (fr)
NZ (1) NZ615070A (fr)
SG (2) SG10201500208SA (fr)
TR (1) TR201903573T4 (fr)
WO (1) WO2011113027A2 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8846603B2 (en) 2010-03-12 2014-09-30 Synageva Biopharma Corp. NPP1 fusion proteins
AR082953A1 (es) 2010-09-09 2013-01-23 Synageva Biopharma Corp Metodos para tratar deficiencia de acido lisosomal lipasa en pacientes
KR20140006037A (ko) 2011-02-15 2014-01-15 시나게바 바이오파르마, 코포레이션 리소좀의 산 리파제 결핍을 치료하는 방법들
MX361434B (es) * 2011-03-11 2018-12-06 Alexion Pharma Inc Proteínas de fusión npp1.
US9744219B2 (en) 2013-02-13 2017-08-29 Yale University Compositions and methods for treating pathological calcification and ossification
EP2994759B1 (fr) * 2013-05-06 2018-09-12 Bio-rad Laboratories, Inc. Stabilisation d'analytes instables dans des matériaux de référence
RU2770698C2 (ru) 2014-12-19 2022-04-21 Алексион Фармасьютикалз, Инк. Способы лечения кальцификации тканей
JP6995627B2 (ja) 2015-05-19 2022-02-04 イエール ユニバーシティ 病的石灰化状態を治療するための組成物およびそれを使用する方法
JP2018537093A (ja) * 2015-11-20 2018-12-20 イエール ユニバーシティ 異所性石灰化障害を治療するための組成物およびそれを使用する方法
EP3827835A1 (fr) * 2016-06-16 2021-06-02 Inozyme Pharma, Inc. Méthodes de traitement d'une prolifération myo-intimale
AU2017306549A1 (en) 2016-08-05 2019-02-21 Yale University Compositions and methods for stroke prevention in pediatric sickle cell anemia patients
US12134790B2 (en) 2017-09-27 2024-11-05 Inozyme Pharma, Inc. Methods of improving cardiovascular function and treating cardiovascular disease using a recombinant ectonucleotide pyrophosphatase phosphodiesterase (NPP1)
WO2020047520A1 (fr) * 2018-08-31 2020-03-05 Yale University Polypeptides enpp1 et leurs procédés d'utilisation
AU2021286502A1 (en) 2020-06-09 2023-01-19 Inozyme Pharma, Inc. Soluble ENPP1 or ENPP3 proteins and uses thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US6825396B2 (en) 1996-06-12 2004-11-30 Board Of Trustees Operating Michigan State University Methods for tissue specific synthesis of protein in eggs of transgenic hens
AU6278298A (en) 1997-02-14 1998-09-08 Salk Institute For Biological Studies, The Methods and compositions for delivery of therapeutic agents to bone tissue employing conjugates of negatively charged peptide oligomers with therapeutic agents
US20040019923A1 (en) 1997-10-16 2004-01-29 Ivarie Robert D. Exogenous proteins expressed in avians and their eggs
ES2357495T3 (es) 1997-10-16 2011-04-27 University Of Georgia Research Foundation, Inc. Aves transgénicas y producción de proteína.
ES2260852T3 (es) 1997-11-07 2006-11-01 Trillium Therapeutics Inc. Metodos y composiciones para inmunomodulacion.
DE20121960U1 (de) 2000-04-06 2004-01-15 Epigenomics Ag Nukleinsäuren für die Diagnose von mit Metastase assoziierten Krankheiten
US20020108132A1 (en) 2001-02-02 2002-08-08 Avigenics Inc. Production of a monoclonal antibody by a transgenic chicken
US7294507B2 (en) 2001-11-30 2007-11-13 Avigenics, Inc. Ovomucoid promoters and methods of use
US6875588B2 (en) 2001-11-30 2005-04-05 Avigenics, Inc. Ovomucoid promoter and methods of use
US7858297B2 (en) 2001-12-18 2010-12-28 Centre National De La Recherche Scientifique Cnrs Chemokine-binding protein and methods of use
WO2003072593A2 (fr) 2002-02-21 2003-09-04 University Of Virginia Patent Foundation Peptides ciblant les os
US20050090001A1 (en) 2003-10-07 2005-04-28 Parker Stephen H. Cell lines and methods for producing proteins
SI3404102T1 (sl) 2004-04-21 2021-11-30 Alexion Pharmaceuticals, Inc. Konjugati za dodajanje kostem in njihova uporaba za ciljanje beljakovin na kosti
WO2006031994A2 (fr) * 2004-09-14 2006-03-23 Xencor, Inc. Domaines fc monomeres des immunoglobulines
GB0426397D0 (en) * 2004-12-01 2005-01-05 Health Prot Agency Fusion proteins
US20090180989A1 (en) * 2005-10-05 2009-07-16 Synageva Biopharma Corp. Compositions and methods for delivering nucleotide sequences to vertebrates
PL2158319T4 (pl) 2007-05-11 2016-04-29 Alexion Pharma Inc Fosfataza alkaliczna kierowana do kości, zestawy i zastosowanie
PE20100141A1 (es) * 2008-05-23 2010-02-22 Wyeth Corp Proteina de union al receptor de interleuquina 21
US8846603B2 (en) 2010-03-12 2014-09-30 Synageva Biopharma Corp. NPP1 fusion proteins

Also Published As

Publication number Publication date
SG10202100341XA (en) 2021-02-25
EP2545080A2 (fr) 2013-01-16
EP2545080B1 (fr) 2017-05-10
BR112013023010A2 (pt) 2018-07-03
JP2014509851A (ja) 2014-04-24
US20150024460A1 (en) 2015-01-22
US20170145393A1 (en) 2017-05-25
ES2716526T3 (es) 2019-06-13
JP2015164427A (ja) 2015-09-17
CL2013002607A1 (es) 2014-03-28
US20210301268A1 (en) 2021-09-30
US20140377859A1 (en) 2014-12-25
US20130273021A1 (en) 2013-10-17
WO2011113027A2 (fr) 2011-09-15
US20230129977A1 (en) 2023-04-27
WO2011113027A3 (fr) 2012-03-01
US8846603B2 (en) 2014-09-30
NZ615070A (en) 2015-10-30
US20140154774A1 (en) 2014-06-05
JP6484905B2 (ja) 2019-03-20
BR112013023010B1 (pt) 2022-05-10
TR201903573T4 (tr) 2019-04-22
US9540621B2 (en) 2017-01-10
EP2545080A4 (fr) 2013-09-11
JP6096826B2 (ja) 2017-03-15
JP2017137318A (ja) 2017-08-10
ES2628841T3 (es) 2017-08-04
JP5735665B2 (ja) 2015-06-17

Similar Documents

Publication Publication Date Title
HK1178908A1 (en) Anticancer fusion protein
EP2616896A4 (fr) Fusion de capteurs
HK1192587A1 (zh) 治療性融合蛋白
SG10201500208SA (en) Npp1 fusion proteins
EP2634188A4 (fr) Dérivé d'aminodihydropyrimidine fusionnée
PT3321287T (pt) Proteínas de fusão e vacinas de combinação
HK1201727A1 (en) Anticancer fusion protein
HK1186192A1 (en) Anticancer fusion protein
IL226481A0 (en) Enzymes@Maochim
ZA201300066B (en) Fusion protein having factor vii activity
EP2698386B8 (fr) Protéine de fusion
EP2657337A4 (fr) Protéine de fusion
HK1187369A1 (en) Fusion protein for secretory protein expression
GB201016494D0 (en) Polypeptide
EP2521787A4 (fr) Expression de protéine améliorée
ZA201207425B (en) Fusion protein
GB201007834D0 (en) Growth promoting fusion proteins
GB201007955D0 (en) Somatosatin fusion proteins
GB201114701D0 (en) Fusion proteins
GB201107189D0 (en) Fusion proteins
GB201010202D0 (en) Fusion polypeptides
GB201007550D0 (en) Modified receptor fusion proteins
GB201004150D0 (en) Modified receptor fusion proteins
PL393146A1 (pl) Przeciwnowotworowe białko fuzyjne
GB201104152D0 (en) Fusion Polypeptide